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ABSTRACT 
 
Aims:The risk of cardiovascular disease (CVD) and mortality is increased in patients 
with chronic kidney disease (CKD), with a background role of vascular calcification in 
the development of CVD also reported. Studies have demonstrated that high 
lipoprotein(a) (Lp(a)) levels accelerate the development of  atherosclerolsis and are 
potentially involved in the vascular calcification.Matrix Gla Protein (MGP) seems to 
play an important role in vascular calcification. The aim of the study was to examine 
the potential association of MGP concentrations with Lp(a) and insulin resistance.  
Methods:The study involved 100patients divided in four groups: 25 with both CKD 
stage 4 and Type2 Diabetes (DM) (Group-A), 25 with CKD4 without DM (Group-B), 
25 non uremic patients with DM (Group-C) and 25 healthy subjects (Group-D). 
Serum glucose, Lp(a), MGP, plasma HBA1c and insulin were measured in all 
patients. Insulin resistance was estimated by the homeostasis model assessment 
equation(HOMA-IR).  
Results:A significant positive linear association between MGP and Lp(a) levels 
(r=0.272,p=0.006) was noted, as well as between MGP and HOMA-IR levels 
(r=0.308,p=0.002). However, no significant linear association between Lp(a) and 
HOMA-IR levels was recorded. A similar positive association between MGP and 
insulin levels (r=0.204,p=0.042) was also found. 
Conclusion:This study concluded that diabetes coexisting with renal disease leads to 
extreme vascular calcification expressed by elevated MGP levels, resulting in higher 
frequency of cardiovascular disease in comparison to CKD patients without diabetes. 
The detected Lp(a) and MGP association in CKD4 patients  may also represent the 
key to the complicated mechanism of their coexisting accelerated atherosclerosis 
and vascular calcification. 
 
 
 
Keywords: Matrix γ-carboxyglutamic acid protein (MGP); insulin resistance; 
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1. Introduction 
 It is commonly accepted that the risk of cardiovascular disease and mortality 
is increased in patients with chronic kidney disease (CKD)
 [1,2].  Cardiovascular disease (CVD) in CKD is associated with arteriosclerosis and 
arterial stiffness [2,3]. Moreover, studies have pointed out the crucial role of vascular 
calcification in the development of CVD especially in certain patient groups, such as 
those with CKD [4,5]. It should be noted that cardiovascular calcifications in patients 
with CKD are more prevalent (up to fivefold more excessive vascular calcification), 
progressive and severe compared to non-CKD population or age-matched 
individuals with coronary artery disease [6,7]. 
Vascular calcification is developed when calcium/calcium phosphate 
complexes deposition occurs in the intima and/or media layers of the vessel and/or 
valvular tissue once they have become mineralized [8]. Pathogenesis of vascular 
calcification is believed to be a multifactorial and multi-step process [9,10]. Numerous 
factors associated with vascular calcification have been identified including duration 
of hemodialysis, hypercalcemia, hyperphoshphatemia, increased calcium x 
phosphorus (Ca x P) product, hyperparathyroidism, diabetes mellitus, dyslipidemia, 
high levels of lipoproteins, urea, homocysteine, parathormone, inflammation, 
oxidative stress and patient’s age [11,]. 
 Pathophysiology and etiopathogenesis of vascular calcification and 
atherosclerosis, in patients with chronic kidney disease remains unclear. It has been 
suggested that a disturbed equilibrium between calcification promoters and inhibitors 
may possibly lead to vascular wall calcification [2]. Vascular calcification process 
may also include the differentiation of vascular smooth muscle cells (SMCs) into 
osteoblast-like cells possibly due to uremic toxins which may accelerate core binding 
factor a-1 (Cbfa1) expression [13]. Other factors involved in the development of 
vascular calcification are the main calcification inhibitory molecules, such as fetuin-A, 
osteoprotegerin (OPG), and the Matrix Gla Protein (MGP) [10,14]. 
MGP, a low molecular weight protein originally isolated from bone, is a 
vitamin K-dependent extracellular matrix protein, known to be synthesized by 
chondrocytes in the cartilage and by vascular smooth cells in the arterial vessel wall 
[15,16]. MGP is involved in modulating vascular calcium metabolism. It belongs to a 
protein family that contains γ-carboxyglutamic acid residues (Gla) which play a key 
role in its calcium binding capacity [17], while undercarboxylated MGP levels were 
inversely associated with the calcification process in patients undergoing 
hemodialysis [18].  
MGP was the first in vivo inhibitor of vascular calcification discovered, 
expressed in abundance in atherosclerotic plaques, although it is present in normal 
artery wall as well. It has been demonstrated that MGP acts as an inhibitor to soft 
tissue calcification [4,19] showing also an inverse association with the severity of 
vascular calcification [20] however, high levels of MGP were detected not only in 
normal blood vessels, but also in calcified human atherosclerotic plaques [21,22]. 
According to previous studies [23,24], uncarboxylated MGP (probably) due to 
deficiency of vitamin K (especially menaquinone K2), as well MGP gene 
polymorphisms [25,26] are associated with the development or progression of 
calcification and may be related to the pathogenesis of cardiovascular events. 
Thus, CKD and dyslipidemia are two significant risk factors for cardiovascular 
disease and atherosclerotic events. Further, metabolic syndrome and diabetes 
  
 
 
mellitus are recognized as two major risk factors for the development not only of 
cardiovascular disease, but also of CKD [27,28]. 
Lipoprotein(a) (Lp(a)), a low density lipoprotein, is associated with 
cardiovascular events and may also represent a link between thrombosis and 
atherosclerotic disease process [29,30]. Studies have also demonstrated that high 
Lp(a) levels, accelerate the development of  atherosclerolsis and are potentially 
involved in the vascular calcification [31,32]. In addition, Lp(a) has been identified 
closely in the calcified lessions of atherosclerotic areas and a potential effect of Lp(a) 
on human vascular smooth muscle cells has been also documented indicating that 
Lp(a) may be involved in vascular calcification [32,33]. 
Given the fact that MGP, synthesized by chondrocytes and vascular smooth 
muscle cells, plays a key role in the inhibition of tissue calcification we tried to 
examine the potential associations of MGP concentrations with Lp(a) levels and 
insulin resistance in patients with CKD and/or DM. 
 
 
  
 
 
2. Material and methods 
 
2.1 Study population 
This study involved 100 participants, recruited through convenience sampling 
attending the outpatient clinics of the involved hospitals. Design was cross-sectional 
including cases and controls. Subjects were divided in four groups: Group A 
consisted of 25 patients with stage 4 chronic kidney disease (CKD4) and diagnosed 
type 2 Diabetes Mellitus (DM), Group B consisted of 25 patients with stage 4 chronic 
kidney disease without diabetes, Group C included 25 patients with DM without 
impaired renal function, and Group D consisted of 25 patients, without chronic kidney 
disease, diabetes or any other major chronic conditions. The subjects of this group 
were considered as healthy subjects (HS). 
All patients included in the study were adults. Inclusion criterion for uremic 
patients was GFR 15-29 ml/min/1.73m2. All patients without diabetes had normal 
fasting glucose levels, normal HBA1c levels and normal glucose tolerance. The study 
was approved by the Local Ethics Committee of the participating hospitals and 
performed in accordance with the Declaration of Helsinki. Written informed consent 
was obtained by all individuals. Data were stored in a secured server, all tests 
contributing to the study database were appropriately anonymised and only 
administrative staff had access to the identifiable files. 
 
2.2 Laboratory measurements 
Medical history and anthropometric parameters were obtained from all 
individuals. In addition, fasting venous blood samples were collected from all 
participants for determining biochemical parameters. Serum glucose, electrolytes, 
cholesterol and plasma HBA1c were measured on an architect (ABBOTT) 16200 
analyzer.   
Serum samples were stored at -80C until process. Lp(a) was measured by 
immunonephelometry using the Abbott Architect ci 16200 analyzer (Abbott Park, IL, 
  
 
 
USA). Immunonephelometry is also mentioned as a way of Lp(a) measurement in 
previous studies [34,35], while being based on previously reported data, Lp(a) 
concentrations >30 mg/dL were indicative of high risk patients [35, 36].  
Plasma insulin was estimated by Microparticle enzyme kits (ABBOTT IMx 
Insulin assay) on an IMx ABBOTT analyzer. GFR was calculated with the MDRD 
equation [37] and insulin resistance was estimated by the homeostasis model 
assessment equation (HOMA-IR) as described by Matthews et al. [38]. The levels of 
hs-CRP in the serum samples were measured with high-sensitivity methods using 
nephelometry (BN II Nephelometer-Siemens).  MGP levels were measured with 
ELISA method (Biomedica Gruppe, Wien, Austria).  
 
 
2.3 Statistical analysis 
Data are shown as mean ± SD (standard deviation) or as numbers (n). All the 
variables were tested for normal distribution using the Kolmogorov-Smirnov test. 
Analysis of variables (ANOVA) was used to compare differences in the studied 
parameters among the four groups. P-values < 0.05 (two-tailed significance) were 
considered statistically significant. When a P-value < 0.05 was found in ANOVA, the 
post hoc LSD was used to look for differences between the study groups. Categorical 
variables were compared by the chi-square test. In order to trace possible linear 
associations between the variables the Pearson correlation coefficient was 
measured. Analysis of data was performed using SPSS 15.0 (Lead Technology Inc).  
 
 
3. Results 
The four groups did not differ significantly in terms of gender, age, waist 
circumference and history of arterial hypertension. However, a statistically significant 
difference in terms of smoking habits (p=0.02), history of heart disease (p<0.001) 
and ischemic stroke (p=0.01) was indicated for group A. Hematocrit, serum levels of 
MGP, high sensitivity CRP (hsCRP), total cholesterol, HDL, LDL, TGs Lp(a), Insulin, 
electrolytes (Ca, P), plasma levels of HbA1c and insulin resistance estimated with 
HOMA-IR were determined for the four groups and they were compared using one-
way ANOVA methodology to detect a statistically significant difference of the means 
between the groups. Demographic and clinical characteristics of the study subjects 
are shown in Table. 
 
 
  
 
 
Table 
Main demographic and clinical characteristics of the study population (total number 
of participants=100) 
 
Group A 
(CKD4+DM) 
Group B 
(CKD4) 
Group C 
(DM) 
Group D 
(HS) 
p-value 
Gender 
(men/women) 
12/13 14/11 11/14 11/14 NS 
Age (years) 67.9±7.4 65.7±12.3 67.7±6.5 65.3±8.1 NS 
Waist 
circumference 
(cm) 
100.7±10.2 94.2±10.4 97.9±11.2 98.3±9 NS 
Heart Disease 
(Y/N) 
12/13a,b,c 6/19a 2/23 0/25 <0.001 
Ischemic 
stroke (Y/N) 
8/17a,c 1/24 4/21 0/24 0.01 
Smoking (Y/N) 9/16b 11/14b 2/23 6/19 0.02 
Dyslipidemia 
(Y/N) 
14/11 9/16 18/7 15/10 NS 
Hypertension 
(Y/N) 
25/0 23/2 21/4 23/2 NS 
Diabetes 
mellitus (Y/N) 
25/0 0/25 25/0 0/25 
 
GFR 
(ml/min/1.73m2) 
17.1±1.51a,b 17.3±1.52a,b 76.8±10.06 76.4±10.84 <0.0001 
  
 
 
 Insulin 
(μUI/ml) 
22.04±15.0a,b 18.16±12.6 12.32±6.49 12.44±7.65 0.005 
 ΗbA1c (%) 7.3±1.2a,c 5.6±0.3b 7.8±1.3a 5.8±0.3 <0.0001 
 HOMA 6.92±6.0a,b,c 4.12±3.02 4.73±2.96 2.94±1.86 0.003 
  Lp(a) (mg/dl) 45.15±50.0a,b 34.98±25.3a 21.04±23.6 10.12±7.22 0.001 
 MGP (nmol/l) 6.22±2.20c 4.84±1.5 5.66±1.12 5.58±0.92 0.01 
hsCRP (mg/l) 21.56±31.4a.b 13.5±24.0 7.55±13.4 3.54±4.03 0.01 
  Ca (mg/dl) 7.64±0.91a,b,c 8.60±0.72a,b,d 9.38±0.50 9.31±0.40 <0.0001 
  P (mg/dl) 5.28±1.17a,b 4.92±1.16a,b 3.35±0.39 3.30±0.54 <0.0001 
  CHOL (mg/dl) 163.6±42.8a.b 173.6±46.7a,b 201.8±41.6 201.7±43.3 0.003 
  HDL (mg/dl) 42.93±12.6b 41.24±11.5a,b 49.6±11.5 48.28±10.5 0.03 
  LDL (mg/dl) 95.7±37.2a,b 107.9±39.5 130.3±33.1 129.5±36.9 0.002 
TGs (mg/dl) 125.0±52.9 122.6±51.2 109.6±43.7 119.6±69.0 NS 
CKD4, chronic kidney disease stage 4; DM, Diabetes Mellitus; HS healthy subjects  
Heart disease is medical history of myocardial infarction, angina, coronary intervention 
procedures, heart failure. 
a
statistically significant compared to HS,  
b
statistically significant compared to DM  
c
statistically significant compared to CKD4,  
d
statistically significant compared to CKD4+DM 
Differences are statistically significant at the 0.05 level 
 
 
 
  
 
 
Insulin resistance was higher in CKD4+DM (group A) in comparison to CKD4 
(group B), DM (group C) and healthy subjects (group D). In addition, HbA1c levels 
were significantly higher in patients of group A compared to group B and group D. 
 MGP serum levels were significantly higher in CKD4+DM patients compared 
to uremic patients without diabetes (CKD4). However, no significant difference of 
MGP serum levels among the other groups was indicated. Lp(a) was found to be 
significantly higher in patients with renal disease stage 4, both with or without 
diabetes mellitus, compared to healthy subjects. Moreover, Lp(a) was significantly 
higher in CKD4+DM patients compared to patients with diabetes without renal failure.  
Total population analyses were performed in order to identify potential 
associations among the parameters. In fact, there was a weak, although highly 
significant, positive linear association between MGP and Lp(a) levels (r=0.272, 
p=0.006), as well as similarly strong association between MGP and HOMA IR levels 
(r=0.308, p=0.002). A similarly positive association between MGP and insulin levels 
(r=0.204, p=0.042), was also found. However, no significant linear association 
between Lp(a) and both HOMA IR and insulin levels was indicated (r=0.122, p=0.097 
and r=0.173, p=0.085, respectively). Given these results we performed further 
subgroup analyses for each category separately and the only association observed 
was between MGP and LP(a) levels only in group A (r=0.455, p=0.022).  
 
 
 
4. Discussion 
This study outlines that MGP and Lp(a) levels, which are indicative of 
vascular calcification and atherogenetic process, play an important role in patients 
with CKD regardless of a diabetes diagnosis.  The majority of patients with chronic 
kidney disease (CKD) have excessive vascular calcification, which is often 
considered a strong prognostic marker of cardiovascular disease and mortality.  
 Our study showed that patients with stage IV CKD and DM have significantly 
higher serum levels of MGP compared to uremic patients without diabetes. However, 
no significant difference in MGP levels was found between the latter and healthy 
subjects. This finding demonstrates that diabetes mellitus, coexisting with renal 
disease, leads to extreme vascular calcification, expressed by elevated MGP levels, 
resulting in the higher frequency of cardiovascular disease in these patients 
compared to patients with CKD and without DM.  
These results concur with a previous study, which found that serum levels of 
MGP were higher in patients with a high number of risk factors for coronary artery 
disease as well as in patients with high overall Framingham coronary heart disease 
risk score [39]. Furthermore, Braam et al. found that levels of circulating MGP in 
patients with type 1 Diabetes Mellitus (which is a risk factor for atherosclerosis) were 
elevated [40]. Our findings concerning the group B of patients (CKD patients without 
diabetes) are in agreement with the results of Jono et al, which detected a reverse 
association between the levels of serum MGP and coronary artery calcification [9].  
Possible explanations of the above findings is that MGP may be induced in 
response to calcification as a local negative feedback mechanism that increases 
MGP levels in calcified human plaque. Thus, a part of MGP that is water-soluble is 
released in circulation and may account for the elevated levels of serum MGP 
  
 
 
observed in atherosclerotic patients. Another potential mechanism is inadequate 
levels or activity of mineralization inhibitor such as MGP in CKD patients [41]. 
Additionally, Lp(a) levels were significantly higher in patients with CKD (with 
or without diabetes) compared to diabetic patients without CKD or healthy 
participants. It should be noted that patients in both categories (namely, CKD+DM 
and CKD) demonstrated particularly elevated levels of Lp(a), indicative of being high 
risk patients [35,36] , while the coexistence of both CKD and DM was accompanied 
with even higher levels of Lp(a), emphasizing the notably increased cardiovascular 
risk in those patients.    
Moreover, an independent and statistically significant positive linear 
association was reported between MGP and Lp(a), as well as MGP and HOMA-IR in 
the total sample population. This suggests an in vivo association of the vascular 
calcification process with atherogenesis and with the insulin resistance 
pathophysiological spectrum. However, in subgroup analyses an association 
between MGP and Lp(a) was observed only in patients with CKD and DM, 
supporting the findings that renal disease and DM comorbidity is associated with an 
even higher cardiovacsular risk.  
Lp(a) levels appeared to be significantly increased in patients with CKD, 
possibly assosiated with genetic as well as other factors related to CKD apart from 
GFR [42]. On the other hand, Lp(a) concentrations were not significantly correlated 
with insulin sensitivity (HOMA-IR) which is consistent with existing literature [43-44]. 
The association between MGP and Lp(a) was consistent with the results of a 
previous study performed in transgenetic rabbits in which Lp(a) levels were 
associated with increased alkaline phosphatase activity and calcium accumulation 
[32]. Moreover, a positive association was also observed in patients with 
cardiovascular disease [45].  A possible explanation could be that Lp(a), and the 
subsequently induced vascular calcification promote the MGP expression by smooth 
muscle cells possibly reflecting a transformation of vascular smooth muscle cells to 
osteoblast-like cells especially in patients with CKD [46]. 
In addition, the recorded significant positive linear association between MGP 
and HOMA-IR reflects the increased vascular calcification process observed in 
patients with diabetes. The pathogenesis of vascular calcification in diabetes is not 
completely understood, though high glucose and other potential factors may play an 
important role by transforming VSMCs into osteoblast-like cells [47]. Our findings are 
consistent with Parker’s et al who found significantly higher levels of uncarboxylated 
MGP (the precursor of MGP) associated with mitral annular calcification and aortic 
stenosis in patients with diabetes compared to those without diabetes [48]. This 
finding supports the hypothesis that MGP plays a key role in the increased vascular 
calcification process observed in patients with diabetes. Further understanding of the 
mechanism by which diabetes induces this complication is needed to design effective 
therapeutic strategies to intervene with this process [46].  
Finally, according to our findings a parallelism between hsCRP and Lp(a) is 
noted. Lp(a) is associated with atherosclerosis, in which inflammation process has 
also been implicated in the pathogenesis of coronary artery disease. hs-CRP is a 
sensitive index of inflammation, however, there is not sufficient scientific 
bibliographical support to indicate a direct association between the latter (namely 
hsCRP) and Lp(a) [49-50]. As a result, due to the limitation of our study and the 
  
 
 
potential confounding factors between the two parameters, more research is needed 
before any conclusion can be drawn. 
 Regarding the limitations of the present study, the relatively small sample size 
may diminish the statistical power and certain secondary observations may not have 
reached statistical significance. Due to lack of resources in recruitment, patient 
matching by predictors of vascular calcification could not be done. Moreover, the 
absence of vascular atherosclerosis estimation and the cross-sectional design does 
not allow the substantiation of an etiological or pathophysiological hypothesis.  
However, to the best of our knowledge, this is the first study that examined 
the MGP levels simultaneously in these four categories and tried to investigate 
possible associations with insulin resistance and Lp(a) levels. 
 
 
 
5. Conclusion 
In conclusion, we have demonstrated that in patients with CKD, the Lp(a) 
were significantly elevated. This is an important finding as the Lp(a) and MGP levels 
association may represent the key to a complicated mechanism of the coexisting 
accelerated atherosclerosis and vascular calcification development in those patients. 
Excessive vascular calcification occurs when diabetes mellitus coexists in CKD 
patients, resulting in higher risk of major cardiovascular events and mortality. MGP 
plays an important, protective, role against this process by acting as a vitamin k-
dependent inhibitor for vascular calcification. However, the mechanism behind the 
vascular effect of MGP in CKD patients without diabetes mellitus would require 
further research exploration. 
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Highlights  
 
 
  
 Diabetes coexisting with chronic kidney disease is associated with elevated 
MGP levels 
 
 A positive association between MGP and both Lp(a) and HOMA IR levels 
was found  
 
 Potential association of Lp(a) and MGP with atherosclerosis & vascular 
calcification 
 
